AbbVie is a leading pharmaceutical company with a diverse portfolio of products and strong revenue growth. The company has a solid track record of increasing dividends and offers an attractive current ...

AbbVie's flagship drug Humira is facing competition from biosimilars, but the company is expected to offset revenue losses in the segment with Skyrizi & Rinvoq. Two real growth drivers for AbbVie are ...

The arthritis drug Humira has been a blockbuster seller for more than two decades. Now some copycats could end Humira's reign. The blockbuster drug Humira has been one of the world's top sellers for ...